Yamanouchi Will Promote Vesicare With 150 Specialty Sales Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.